No-leaching. No-resistance. No-toxicity. >99.999% Introducing BIOGUARD. Best-in-class dressings for your infection control program

Similar documents
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS

SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data

Redefining Infection Management. Proven Clinical Outcomes

EcoHydra Antimicrobial Handwash. Product Overview. Physical Properties. Product Description. Regulatory Compliance. Key Features and Benefits

3 Infection Prevention Solutions

Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria

Overview of Infection Control and Prevention

Cleaning and Disinfection Protocol Vegetative Bacteria

Other Beta - lactam Antibiotics

TEAT DIP- POST DIP- PRE DIP- STRIPING

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

INFECTION PREVENTION SILVER ANTI-MICROBIAL TEXTILES

SYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data

AHFA 2016 Regulatory Summit. Antimicrobial Material Preservatives & Sustainability Considerations

Appropriate antimicrobial therapy in HAP: What does this mean?

Clorox Germicidal Wipes & Spray. The Easy & Most Effective Way to Disinfect

A solution for current veterinary challenges

Antibacterial Agents & Conditions. Stijn van der Veen

Multi-Drug Resistant Organisms (MDRO)

Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms

Interrupting The ECMO Circuit

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS

Hand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection.

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Post-operative surgical wound infection

EMBEDDED ANTIMICROBIALS IN HEALTHCARE STORAGE & TRANSPORT EQUIPMENT

Problem: Hospital Acquired Infections

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.

Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method.

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)

Summary of the latest data on antibiotic resistance in the European Union

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus

WHY IS THIS IMPORTANT?

Epidemiology and Economics of Antibiotic Resistance

TECHNICAL BULLETIN PURELL Advanced with Aloe Instant Hand Sanitizer

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance

Antimicrobial Resistance

Antimicrobial Resistance Acquisition of Foreign DNA

CONTAGIOUS COMMENTS Department of Epidemiology

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY

Human health impacts of antibiotic use in animal agriculture

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

Concise Antibiogram Toolkit Background

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

BactiBarrier Testing and Analysis

Two (II) Upon signature

Is biocide resistance already a clinical problem?

In-Service Training Program. Managing Drug-Resistant Organisms in Long-Term Care

Antimicrobial Stewardship:

Antimicrobial Resistance

99.999% KILLS UP TO. MICROBES to help prevent healthcare-associated Infections

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

HOSPITAL-ACQUIRED INFECTION/MRSA EYERUSALEM KIFLE AND GIFT IMUETINYAN OMOBOGBE PNURSS15

Antimicrobial Stewardship Strategy: Antibiograms

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare

PVA Sponge Products. Bacteriostatic PVA sponges

Methicillin-Resistant Staphylococcus aureus

Burn Infection & Laboratory Diagnosis

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

Testimony of the Natural Resources Defense Council on Senate Bill 785

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent

Inhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani

running head: SUPERBUGS Humphreys 1

June 12, For animal antibiotics, the safety assessment is more stringent than that for human antibiotics in three ways:

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007

Surgical site infections. J Scott Weese DVM DVSc DipACVIM

Nosocomial Antibiotic Resistant Organisms

Healthcare-associated infections surveillance report

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

ESCMID Online Lecture Library. by author

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

SSTI s :A Guideline for Effective Treatment of Skin and Soft Tissue Infections

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

The Choice. V e r s a t i l i t y. S t r e n g t h. F l e x i b i l i t y. of surgeons for half a century

MRSA Outbreak in Firefighters

Transcription:

Introducing BIOGUARD No-leaching. >99.999% No-resistance. No-toxicity. Just cost-efficient, broad-spectrum, rapid effectiveness you can rely on. Best-in-class dressings for your infection control program

A perfect dressing for infection prevention BIOGUARD Barrier Dressings with their patented active component and patented method of fabrication are designed specifically to act as a barrier to bacterial invasion of wounds. No Toxicity. Due to its patented manufacturing process, the active component within BIOGUARD Barrier Dressings is intrinsically bound to the base substrate it does not leach away from the dressing. This is important as leaching antimicrobials can be toxic to good cells. BIOGUARD is the only non-leaching dressing of its kind. No Resistance. Due to the active components relatively large size, and the non-leaching attributes of the dressing, bacteria can not develop resistance to BIOGUARD dressings. This is a vital benefit of a dressing being considered for infection protection and widespread usage. BIOGUARD Barrier Dressings offer clinicians a truly unique and ideal line of barrier dressings that can play an important role in a facility s overall infection protection program.

BIOGUARD Barrier Dressings have Wound infection, by the numbers: 2.7%: The percentage of surgical interventions complicated by a Surgical Site Infection (SSI) (over 500,000 in the US annually) 1 2 out of 3: Surgical treatments of skin and debridement of wound infections are 2 out of 3 of the top procedures associated with the treatment of MRSA infections 2 2005: The year deaths attributable to MRSA began to exceed deaths attributable to HIV/Aids in the US 3 $25,546: The average incremental cost of an SSI 4 October 1, 2008: The day Medicare stopped paying for certain catheter associated infections and surgical site infections 5 8000 CFUs wound bacteria per cubic meter of air: is released with each gauze dressing change increasing potential of cross contamination 6 Three: The number of key characteristics wound care physicians consistently describe as the ideal dressing for prophylaxis use: + Non-toxic must not disrupt wound healing. + Elimination of antimicrobial resistance with widespread usage on large numbers of wounds, this is a must-have. + Cost-effective and easy to use Transitions easily into existing care protocols. been proven to prevent bacterial penetration and inhibit growth within wound dressings. BIOGUARD provides a barrier to bacterial penetration, and results in >5-log (99.999%) kill of a broad spectrum of microbes including antibiotic resistant organisms. The active component within BIOGUARD is a cationic biocide called PolyDADMAC (poly diallyl dimethyl ammonium chloride). PolyDADMAC shares the same compound class as PHMB (poly hexadine methyl biguanide), with two key differences: It is intrinsically bound to the base dressing substrate, unlike PHMB, which leaches away from the dressing. It is significantly larger than PHMB, with a molecular weight of 200,000 250,000 g/mol (PHMB molecular weight = 2,000 4,000 g/mol).* *See method of action

Why does leaching matter? Figure 1: A Short Course on Zone of Inhibition (ZOI) For wounds that are either critically colonized or infected, bacterial control even at the expense of some good cells is paramount. For antimicrobials such as silver dressings, this is standard course of action. That s why these dressings are generally limited to critically colonized/infected situations for a maximum duration of 4 weeks. For wounds that are sterile, contaminated, or colonized, the main goal is wound healing (while avoiding critical colonization or infection). For these wound types, only dressings that are non-toxic to healthy cells should be considered. (See Fig.1) Also when considering dressings as prophylaxis and as an important part of an infection prevention program, only dressings that consistently demonstrate no chance of causing antimicrobial resistance should be considered. Leaching leads to sub-minimum inhibitory concentrations, which can lead to resistant strain formation. What about size? Most causes of antimicrobial resistance occur when the active component enters into the cell of the pathogen. With a molecular weight up to 100x larger than PHMB, PolyDADMAC simply won t fit through holes in the damaged cell walls of microbes. 100 98 Figure 1. BIOGUARD SILVER DRESSING BIOGUARD shows no zone of inhibition, and direct contact testing with L929 fibroblast cell line shows normal healthy growing cells. This market leading silver dressing shows a zone of inhibition where the chemical leaches out of the dressing: the effect of leached silver is shown in the direct contact assay by malformed and depopulated cells. Figure 2: Direct Exposure to the Treated Surface 99.988 99.994 99.999 99.999 99.999 99.999 99.999 99.990 99.999 99.948 In this standard antimicrobial resistance assay (See Fig.2), consistent exposure to PolyDADMAC for a prolonged period of time showed no resistance to the biocide treated substrate. Throughout a 10-round step-by-step adaptation training test, bacterial cells were exposed to PolyDADMAC. From each round only bacterial survivors were propagated into a new inoculum. Even after continued exposure to the biocide (10X), no resistance was formed. Inactivation % 96 94 92 90 1 2 3 4 5 6 7 8 9 10

Method of Action The active in BIOGUARD Barrier Dressings PolyDADMAC is an advanced cationic biocide polymer with a high charge density and high molecular weight, permanently bound to the barrier dressing. Cationic biocides include surface active quaternary ammonium compounds, or Quats. Quats attract bacterial cells and bind rapidly to the cellular envelope to displace otherwise stable calcium ions and physically disrupts the cell wall structures (See Fig.3). Cationic biocides cause the membrane to fragment, leading to generalized cellular leakage. The higher the charge density, the more likely the Quat s effects will not be diluted in high levels of exudate or other bodily fluids. SEM image of health, highly-populated Escherichia coliform cells on untreated gauze. Escherichia coliform cells after exposure to Bioguard. Since the active agent is permanently bound to the barrier dressing, there is no leaching and no depletion of the biocide reservoir. This means the active agent within the dressing can never fall below the minimum inhibitory concentration (MIC). Additionally, bacteria cannot develop resistance to an agent that they cannot internalize. Due to the relatively high molecular weight of its active agent, only BIOGUARD Barrier Dressings do not pose this risk. Figure 3: Unique 3-Stage Method of Action Attract Bind Disrupt & Destroy Broad spectrum and fast-acting Test Species* Average Log Reduction Methicillin resistant staphylococcus aureus: 7.76 MRSA Staphylococcus aureus 6.90 Escherichia coliform 7.94 Pseudomonas aeruginosa 7.61 Micrococcus luteus 6.42 Streptococcus pyogenes 7.72 Enterococcus faecium 5.74 Staphylococcus epidermidis 7.73 Listeria monocytogenes 7.59 Vancomycin Resistant Enterococcus faecium: VRE 7.30 Serratia marcescens 7.43 Klebsiella pneumoniae 7.39 *Testing method AATCC 100. The clinical significance of this testing is not proven. Time Staph. Aureus E. Coli P. Aeruginosa 1 min. 99.98780% 99.99842% 99.98205% 10 min. 99.99415% 99.99763% 99.98564% 20 min. 99.99268% 99.99938% 99.99397% 30 min. 99.99878% 99.99972% 99.99746% 60 min. 99.9999% 99.99946% 99.99936% 4 hrs. 99.9999% 99.99981% 99.99996% 8 hrs. 99.9999% 99.99997% 99.99996% 12 hrs. 99.9999% 99.99997% 99.99996%

Target pathogens effectively and cost-efficiently with BIOGUARD Barrier dressings. + Completely Non-Toxic + Proven broad spectrum activity + Quick, durable action + No chance of causing resistant strains Conforming Bandages 97241 2" x 4.1 yds 1 roll/pkg, 100 pkgs/case A6266 97341 3" x 4.1 yds 1 roll/pkg, 100 pkgs/case A6266 97441 4" x 4.1 yds 1 roll/pkg, 100 pkgs/case A6266 Large Gauze Roll 97322 6-ply, 4 ½" x 4.1 yds 1 roll/pkg, 100 pkgs/case A6266 Gauze Sponges 97208 8-Ply, 2" x 2", 2 s 100 dressings per tray, A6222 30 trays/case 97412 12-Ply, 4" x 4", 2 s 50 dressings per tray, A6222 24 trays/case Packing Strips 97831 ¼" x 5 yds 12/cs A6266 97832 ½" x 5 yds 12/cs A6266 97833 1" x 5 yds 12/cs A6266 Non-Adherent Dressings 97334 3" x 4" 50/box, 18/cs A6222 97338 3" x 8" 50/box, 12/cs A6223 Island Dressings 97041 4" x 10" 25/box, 4 boxes/cs A6203 97042 4" x 14" 25/box, 2 boxes/cs A6204 97045 4" x 5" 25/box, 8 boxes/cs A6203 97048 4" x 8" 25/box, 4 boxes/cs A6203 dermasciences.com Derma Sciences, Inc. 214 Carnegie Center, Suite 300 Princeton, NJ 08540 U.S. Market: (800) 445-7627 Canadian Market: (800) 387-5302 BIOGUARD is a registered trademark of Derma Sciences, Inc. Ready Cut Gauze Burn Dressing 97118 100-Ply, 18" x 18" 1pkg, 10 pkgs/cs A6224 US Patent Nos. 7,045,673, 7,709,694 and 7,790,217 and foreign counterparts. NIMBUS technology is licensed to Derma Sciences, Inc. by Quick-Med Technologies, Inc. NIMBUS is a registered trademark of Quick-Med Technologies, Inc. References: 1. Stone, P et al. Systematic review of economic analyses of health care-associated infections, Am J Infect Control 2005;501-509, Vol 33 No. 9. 2. Healthcare-Associated Methicillin Resistant Staphylococcus aureus (HA-MRSA); Centers for Disease Control and Prevention;www.cdc.gov/ncidod. 3. Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States. A CDC Report; Journal of the American Medical Association; Oct 2007. 4. Stone, P et al. A systematic audit of economic evidence linking nosocomial infections and infection control intervention: 1990 2000. Am J infect Control 2002; 145-152, Vol 30. 5. Medicare nonpayment for medical errors, National Conference of State Legislatures, Aug 2008. 6. Lawrence, JC et al. Wound dressings and airborne dispersal of bacteria. Lancet 1992; 807, Vol 339. CATBIOBROCH 0713